BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, December 26, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

April 24, 2017

View Archived Issues

Rigel synthesizes fused imidazole and pyrazole derivatives as TGF-beta inhibitors

Read More

BeiGene initiates pivotal trial of BGB-A317 in China for classical Hodgkin's lymphoma

Read More

ReViral reports topline phase I data on RV-521 for RSV

Read More

Starpharma achieves preclinical milestone under AstraZeneca license agreement

Read More

FDA approves infliximab biosimilar Renflexis

Read More

Preliminary phase III data for sublingual treatment for Parkinson's disease 'off' episodes

Read More

Novartis presents phase IIa data for BPS-804

Read More

Roche studies RO-7020531 in phase I for chronic hepatitis B

Read More

EMA committee recommends approval of inotuzumab ozogamicin

Read More

PreveCeutical Medical and UniQuest sign research and option agreement

Read More

Atara and Merck & Co. in clinical trial collaboration to evaluate ATA-129 with pembrolizumab

Read More

Spinraza recommended for approval in E.U.

Read More

Phase III data presented for Hizentra for the treatment of myasthenia gravis

Read More

AbbVie conducting second phase III study of ABT-494 in psoriatic arthritis

Read More

EMA's CHMP recommends approval of Brineura for CLN2 disease

Read More

Wockhardt patents novel antibacterials

Read More

Sandoz rituximab and etanercept biosimilars recommended for approval in E.U.

Read More

EMA committee recommends E.U. approval of Kevzara

Read More

EMA committee adopts positive opinion on Opdivo in locally advanced or metastatic urothelial cancer

Read More

Reprogramming mouse astrocytes rescues aspects of motor behavior in a model of Parkinson's disease

Read More

Model of obesity and chronic liver disease allows study of effects on hepatic encephalopathy

Read More

FDA allows trials of inhaled BIO-11006 in adults with lung cancer

Read More

Janssen Holding publishes provisional notice of end result of Actelion tender offer

Read More

ND0612, a new formulation for subcutaneous infusion of levodopa/carbidopa in advanced PD

Read More

Tiziana obtains approval in Israel of phase II trial protocol for milciclib in refractory HCC

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing